Let’s play devils advocate for a minute. If Missling we as confident as some on this board that say “we got this” why wouldn’t he be more open? Or at the very minimum be a little more forthcoming with what we have? Might it be because he isn’t so confident yet? And is awaiting the results of the current trials?
If he doesn’t end up getting a drug to market will you still commend his leadership and strategy?
I think Missling has done a great job at managing money and funding for trials. My problem with Missling is the self imposed missed timelines, time in which takes to enroll patients, time in which it takes him to release data. Basically his over all time management. That matters in a publicly traded company. As we are currently witnessing.
Hard to be too disappointed in a $17 price today, given the 52 week low of $3.75.
No reason to believe that we won't see another 5-fold price increase in the next 12 months, given the solid AVXL that has been meticulously laid under the direction of TGD.
Five years of available cash, no debt, and a massive pipeline built upon a solid foundation of testing and research.
Market Data 
Markets 
AI
